Horizon Therapeutics plc Announces U.S. FDA Approval of New Dosage Form for Procysbi (Cysteamine Bitartrate) Delayed-Release Oral Granules

DUBLIN--(BUSINESS WIRE)--February 18, 2020 -- Horizon Therapeutics plc (Nasdaq: HZNP) announced today that the U.S. Food and Drug Administration (FDA) has approved Procysbi® (cysteamine bitartrate) delayed-release oral granules in packets for...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news